EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study

Eri Iwata, Mitsushige Sugimoto, Daisuke Asaoka, Mariko Hojo iD, Masayoshi Ito, Naoko Kitazawa, Naoto Kurihara, Tatsuhiro Masaoka, Shigeaki Mizuno, Hideki Mori, Akihito Nagahara, Ryota Niikura und 11 weitere

Helicobacter · 2024

DOI: 10.1111/hel.13125 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Eri Iwata und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The situation of Helicobacter pylori eradication therapy has been changing over time, owing to increases in antimicrobial‐resistant strains, lifestyle improvements, and changes in indications for eradication. In Japan, eradication therapy is now available to all H. pylori ‐positive patients under the medical insurance system, and the potassium‐competitive acid blocker vonoprazan has been used for eradication from 2015. Recently, with the aging of society, opportunities to provide eradication to elderly patients are increasing, but the current status and effectiveness of eradication in elderly patients remains unclear. Therefore, we aimed to investigate the trends of H. pylori eradication in a metropolitan area to determine the factors associated with successful H. pylori eradication in elderly patients older than 80 years.

Methods

Trends in the eradication rates of patients who received first‐ or second‐line eradication at 20 hospitals in the Tokyo metropolitan area from 2013 to 2023 were investigated.

Results

The eradication rates in the per‐protocol analysis were 82.3% (95% confidence interval [CI]: 81.2%–83.2%) for the first‐line treatment ( n = 6481), and 87.9% (86.9%–88.9%) for the second‐line treatment ( n = 4899). Multivariate analysis showed that independent factors for successful eradication in the first‐line treatment were an age of older than 80 years (OR: 0.606; 95% CI: 0.448–0.822), peptic ulcers (vs. atrophic gastritis: 3.817; 3.286–4.433), and vonoprazan (vs. proton pump inhibiters (PPIs), 3.817; 3.286–4.433), and an age of older than 80 years (0.503; 0.362–0.699) and vonoprazan (1.386; 1.153–1.667) in the second‐line treatment.

Conclusion

After 2015, the eradication rate of both first‐ and second‐line therapies were maintained at a higher level than before 2015, owing to the use of vonoprazan. As the H. pylori eradication rate in patients older than 80 years was low, an effective strategy for these patients needs to be developed in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriAged, 80 and overFemaleHumansMaleDrug Therapy, CombinationJapanProton Pump InhibitorsPyrrolesRetrospective StudiesSulfonamidesTokyoTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pylorielderly patientseradication therapypeptic ulcervonoprazan

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAnti-Bacterial AgentsProton Pump InhibitorsPyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan.
  • Division of Genome-Wide Infectious Microbiology, Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Oita, Japan.
  • Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.
  • Department of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Department of Gastroenterology, Yotsuya Medical Cube, Tokyo, Japan.
  • Department of Gastroenterology, Foundation for Detection of Early Gastric Carcinoma, Tokyo, Japan.

ORCID-Profile: Mariko Hojo, Hidekazu Suzuki

Zitieren

APA

Iwata, E., Sugimoto, M., Asaoka, D., Hojo, M., Ito, M., Kitazawa, N., Kurihara, N., Masaoka, T., Mizuno, S., Mori, H., Nagahara, A., Niikura, R., Ohkusa, T., Sano, M., Shimada, Y., Suzuki, H., Takeuchi, Y., Tanaka, A., Tokunaga, K., …, & Kawai, T. (2024). Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study. Helicobacter. https://doi.org/10.1111/hel.13125

Vancouver

Iwata E, Sugimoto M, Asaoka D, Hojo M, Ito M, Kitazawa N, et al. Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study. Helicobacter. 2024. doi:10.1111/hel.13125

BibTeX
@article{Iwata2024,
  author = {Iwata, Eri and Sugimoto, Mitsushige and Asaoka, Daisuke and Hojo, Mariko and Ito, Masayoshi and Kitazawa, Naoko and Kurihara, Naoto and Masaoka, Tatsuhiro and Mizuno, Shigeaki and Mori, Hideki and Nagahara, Akihito and Niikura, Ryota and Ohkusa, Toshifumi and Sano, Masaya and Shimada, Yuji and Suzuki, Hidekazu and Takeuchi, Yoshiaki and Tanaka, Akifumi and Tokunaga, Kengo and Ueda, Kumiko and Sakaki, Nobuhiro and Takahashi, Shin'ichi and Kawai, Takashi},
  title = {Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13125}
}
Kostenlos starten →